Intellia Therapeutics, Inc. NTLA

Bullish…..$NTLA co-founder won Nobel prize last year for finding ? editing Only up baby!

Don’t listen to the bit@&$. It’s a diamond hand., going to rip teddy a&&es …???buy buy buy $NTLA

How CRISPR gene editing will treat diseases in future: Nobel-winning Intellia co-founder Jennifer Doudna
PUBLISHED WED, JUN 30 2021 10:04 AM EDT
UPDATED WED, JUN 30 2021 10:17 AM EDT
Ian Thomas
SHARE

KEY POINTS
CRISPR gene editing, which slices DNA to treat diseases, had its first-ever systemic delivery in a human body.
Jennifer Doudna, who won the 2020 Nobel Prize in chemistry for her work on CRISPR, called the early success of the technology "one of the fastest rollouts I think of technology from the fundamental, initial science to an actual application."
Intellia Therapeutics, the biotech she co-founded, has seen its stock rise over 100% this month.
In this article

REGN
NTLA

Gene-editing technology CRISPR reached a major milestone this past weekend, completing its first systemic delivery as a medicine to a human body.

CRISPR, or clustered regularly interspaced short palindromic repeats, effectively cuts genomes and slices DNA to treat genetic diseases.

The latest breakthrough, the result of a trial between biotech company Regeneron and Boston-based startup Intellia Therapeutics, treated a rare disease after being given as an IV infusion. Previously, other applications of the CRISPR technology had been limited to ex vivo therapy, or where cells are removed from the body for genetic manipulation in a laboratory and then reintroduced to the body.

Jennifer Doudna, who was awarded the 2020 Nobel Prize in chemistry for her work on CRISPR gene editing and is the co-founder of Intellia, recently told CNBC the evolution of the technology from the publication of her early work to clinical trials showing it to be effective in treating diseases in less than 10 years represents, "One of the fastest rollouts I think of technology from the fundamental, initial science to an actual application."

"It's largely because the technology comes at a moment when there's enormous demand for genome editing, as well as a lot of knowledge about genomes," Doudna said at the recent CNBC Global Evolve Summit in mid-June.

As for what's next, Doudna highlighted several challenges and opportunities on the horizon for CRISPR.

Delivery of CRISPR remains a big challenge

While the technology has continued to advance, the task of getting the edited molecules to travel in the body to the cells in the areas where they are needed remains a challenge.

"This is especially an issue in clinical medicine where being able to edit brain cells, heart cells or muscle cells has incredible potential but right now we don't really have the tools to introduce the editors into those cells," Doudna said. "We have the editors; we just don't know how to get them where they need to go."

Sickle cell anemia has been an early focus

Much of the success of the applications of CRISPR thus far has been with ex vivo therapy, where extracted cells are manipulated in a laboratory and then reintroduced into a patient.

Sickle cell anemia, which is passed down genetically and affects approximately 100,000 Americans, according to the CDC, has been a particularly good target for the technology as blood stem cells can be "harvested, edited and then reintroduced to patients," Doudna said.

Genetic diseases of the eye have also been a focus for CRISPR applications as Doudna said "it's easier certainly to deliver to the eye than to other parts of the body."

Delivering the edited cells to the liver has also proven to be easier thus far. "A liver is an organ that naturally takes up molecules in the body," she said.

Any progress in eradicating the more than 100 liver diseases could have a major impact on the lives of Americans. At least 30 million people, or one in 10 Americans, has some sort of liver disease, according to the American Liver Foundation.

Focusing next on the brain, heart, muscles

The next step for innovation around CRISPR will be getting those cells to other parts of the body, such as the brain, the heart and muscles, Doudna said.

"There are some technologies already that enable some of this, for example using various kinds of viruses or virus-like particles, and I'm excited about the innovation that will come in the next few years in this regard," she said.

The cost of treatment is a concern

But as the technology improves and scientists gain the ability to target diseases all across the body, Doudna said that for CRISPR technology to be "widely impactful," it will need to be cheaper.

Treating sickle cell disease with CRISPR therapy, Doudna said, costs about $2 million a patient.

"That is clearly not a price point that will make this available to most people that can benefit from it," she said.

While addressing delivery challenges may also help lower costs, Doudna said that the medical field needs to figure out how to "scale the molecule production so that we reduce costs."

Applying CRISPR to agriculture

The advancement of CRISPR technology can also have an impact on other industries, with agriculture being one of the first to benefit.

Rather than trying to address genetic issues through breeding which can take months to years, or current methods for genetically modifying crops that have boomed in recent decades but involve inserting biological material from other species, the CRISPR technology can manipulate the genes of plants "without touching anything else," Doudna said.

"This is opening the door to lots of things now that can be done to both address challenges of climate change, dealing with drought conditions, introducing traits in the plants that give them protection against pests," she said.

In this article

REGN
NTLA
RELATED
1
CRISPR gene-editing treatment could reach patients ‘very, very soon’: Intellia CEO
2
How CRISPR gene editing will treat diseases in the future, according to one of its creators
3
Pfizer CEO sees a return to 'normal' globally by the end of 2022
4
Air travel in Asia won’t return to pre-Covid levels ‘anytime soon,’ says Singapore minister
5
The new U.S. plan to rival China and end cornering of market in rare earth metals
View the full site
© 2021 CNBC LLC. All Rights Reserved. A Division of NBCUniversal

Data is a real time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stocks, Quotes, and Market Data, and Analysis.

Privacy Policy Do Not Sell My Personal Information CA Notice Terms of Service

Data also provided by

According to Forbes:

Looking at the recent rally, the 15% rise for NTLA stock over the last five days compares with a 2.6% gain seen in the broader S&P 500 index. Now, is NTLA stock poised to rise further? It looks that way. Based on our machine learning analysis of trends in the stock price over the last few years, we believe that there is a strong 64% chance of a rise in NTLA stock over the next month (twenty-one trading days). See our analysis on Intellia Therapeutics Stock Chances of Rise for more details.

Why it’s trading this late right now? Who is buying & selling at $155

F” all the rotten bears here

Names James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary

Published: Jun 24, 2021

CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics (NASDAQ: NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the appointment of James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary.

Mr. Basta is coming to Intellia with more than 25 years of combined in-house corporate and law firm experience, most recently as Chief Legal Officer at Kura Oncology. Prior to Kura, Mr. Basta served in various roles in the legal department at Biogen including as Senior Vice President, Chief Corporation Counsel, where he managed the legal representation for Biogen’s securities filings, board of directors, business development, finance and tax, corporate affairs, employment and information technology. Prior to joining Biogen in 2006, he was a Partner at Baker & McKenzie.

Basically Basta James acquired 130,000 shares at price $171.65 on 7/1/2021 of which 25% will vest 7-1-22. And 75% will vest in 36 substantially equal monthly installments thereafter. Clearly, $NTLA projects it’s stock value to be above & beyond $250 in near future since shares were offered at $171. 65. This is great news ?? don’t let FUD scare your interest or hold in $NTLA. This stock gonna be worth over $500 in less than 6 months

$NTLA has solid strong partnerships w Novartis, Regeneron and many researches in the making. Also w Ospedale San Raffaele, Teneobio inc, & GEMoaB shares many projects. With $NTLA unique scope, success w next sun rise. Hold strong and long. People are still trying to get on it. Volume was real nice despite red market

So w current news, does it mean price offering was over $145. Bc shares acquired were at a price around $175. Could someone explain what it means for $NTLA share price moving forward